Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ: PLRZ )

0.6800 -0.0200 (-2.86%)
Streaming Delayed Price Updated: 3:55 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,550
Open 0.7200
Bid (Size) 0.6600 (1)
Ask (Size) 0.7600 (1)
Prev. Close 0.7000
Today's Range 0.6700 - 0.7200
52wk Range 0.6678 - 4.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
From Polyrizon Ltd.
Via GlobeNewswire

Performance

YTD
-62.84%
-62.84%
1 Month
-38.18%
-38.18%
3 Month
-34.62%
-34.62%
6 Month
-56.13%
-56.13%
1 Year
-56.13%
-56.13%

More News

Read More
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Gains Over 1%, General Mills Shares Fall
Via Benzinga
Exposures Fossil Fuels
What's Going On With Polyrizon Shares Wednesday?
Via Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3
Via Benzinga
Topics Stocks
Exposures US Equities
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Heritage Distilling, Dynamix Open For Trading
Via Talk Markets
Topics Initial Public Offering Stocks / Equities
Exposures Securities Market
BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $4.2M in Initial Public Offering
Via Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
Via ACCESSWIRE
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.